Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 10/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418316 | 0.87 | HSD17B1 (0.49) | HSD17B1HSD17B2CYP3A4CYP2C9ASIC3 | |
| SCHEMBL28116354 | 0.87 | ASIC3 (0.53) | HSD17B1HSD17B2ASIC3KMO | |
| SCHEMBL12408985 | 0.87 | ASIC3 (0.53) | HSD17B1HSD17B2ASIC3KMO | |
| SCHEMBL25633157 | 0.85 | ASIC3 (0.52) | HSD17B1HSD17B2ASIC3KMO | |
| SCHEMBL912763 | 0.82 | ASIC3 (0.63) | MAPKAPK2ASIC3 | |
| SCHEMBL29578028 | 0.82 | ASIC3 (0.63) | MAPKAPK2ASIC3 | |
| SCHEMBL24291931 | 0.81 | ASIC3 (0.61) | MAPKAPK2ASIC3 | |
| SCHEMBL17694751 | 0.81 | ASIC3 (0.61) | MAPKAPK2ASIC3 | |
| SCHEMBL29794052 | 0.81 | ASIC3 (0.61) | MAPKAPK2ASIC3 | |
| SCHEMBL29854571 | 0.81 | ASIC3 (0.61) | MAPKAPK2ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20210111345-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2021-04-15 | — | — | US | disclosed |
| WO-2019179909-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210111345-A1 | METAL COMPLEXES | NCLN, BICRA, AP3M1 | HSD17B1 4561/4885HSD17B2 4525/4885CYP3A4 2923/4885 |
| US-11917903-B2 | Metal complexes | NCLN, BICRA, AP3M1 | HSD17B1 4561/4885HSD17B2 4525/4885CYP3A4 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.